SAPRISARTAN POTASSIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H21BrF3N4O4S.K
Molecular Weight	649.521
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[K+].CCC1=NC(C2CC2)=C(N1CC3=CC4=C(OC(=C4Br)C5=C([N-]S(=O)(=O)C(F)(F)F)C=CC=C5)C=C3)C(N)=O

InChI

InChIKey=IASZJGRIPLTJMA-UHFFFAOYSA-N

InChI=1S/C25H21BrF3N4O4S.K/c1-2-19-31-21(14-8-9-14)22(24(30)34)33(19)12-13-7-10-18-16(11-13)20(26)23(37-18)15-5-3-4-6-17(15)32-38(35,36)25(27,28)29;/h3-7,10-11,14H,2,8-9,12H2,1H3,(H2,30,34);/q-1;+1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7932534 | https://adisinsight.springer.com/drugs/800002559

Saprisartan (formerly known as GR 138950) was developed as a potent long-lasting angiotensin II (AT1) receptor antagonist with high oral bioavailability. The drug was used for the treatment of hypertension and heart failure. However, these studies were discontinued.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Type-1 angiotensin II receptor 40 Target ID: P30556 Gene ID: 185.0 Gene Symbol: AGTR1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/7853190	Antagonist 2778

PubMed

Title	Date	PubMed
Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist.	1995 Feb	7853190

Patents

Name

Type

Language

SAPRISARTAN POTASSIUM

Official Name

English

SAPRISARTAN POTASSIUM [USAN]

Common Name

English

GR138950C

Code

English

1-((3-BROMO-2-(2-(((TRIFLUORO-METHYL)SULFONYL)AMINO)PHENYL)-5-BENZOFURANYL)METHYL)-4-CYCLOPROPYL-2-ETHYL-1H-IMIDAZOLE-5-CARBOXAMIDE POTASSIUM

Systematic Name

English

Saprisartan potassium [WHO-DD]

Common Name

English

1-[[3-Bromo-2-[O-(1,1,1-(trifluoromethanesulfonamido)phenyl]-5-benzofuranyl]methyl]-4-cyclopropyl-2-ethylimidazole-5-carboxamide, monopotassium salt

Common Name

English

GR-138950C

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C66930